Invivyd (IVVD) Net Income (2021 - 2025)
Invivyd (IVVD) reported Net Income of -$12.6 million for Q4 2025, up 34.71% on a YoY basis from -$9.3 million in Q4 2024, and down 13.9% quarter-over-quarter from -$11.0 million in Q3 2025.
Invivyd (IVVD) Net Income (2021 - 2025) Analysis & Trends
Invivyd has reported Net Income for 5 years, with the latest figure at -$12.6 million in Q4 2025.
- For the quarter ending Q4 2025, Net Income rose 34.71% year-over-year to -$12.6 million; the trailing twelve-month figure through Dec 2025 stood at -$55.6 million (up 68.59% YoY), and the FY2025 full-year result was -$55.6 million, up 68.59% from the prior year.
- Net Income for Q4 2025 stood at -$12.6 million, down from -$11.0 million in the prior quarter.
- The five-year high for Net Income was -$11.0 million in Q3 2025, with the low at -$100.7 million in Q1 2022.
- Historically, Net Income has averaged -$46.0 million across 5 years, with a median of -$46.7 million in 2022.
- Annual changes were most pronounced in 2022 — Net Income plunged 160.25% — and 2025, when it soared 82.31%.
- Invivyd's Net Income stood at -$83.1 million in 2021, then soared by 41.98% to -$48.2 million in 2022, then tumbled by 59.2% to -$76.8 million in 2023, then soared by 74.95% to -$19.2 million in 2024, then soared by 34.71% to -$12.6 million in 2025.
- The last three Net Income figures came in at -$12.6 million (Q4 2025), -$11.0 million (Q3 2025), and -$15.1 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Invivyd | 168.41 Mn | -58.28 Mn | - | -12.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12.56 Mn |
| Sep 30, 2025 | -11.02 Mn |
| Jun 30, 2025 | -15.06 Mn |
| Mar 31, 2025 | -16.92 Mn |
| Dec 31, 2024 | -19.23 Mn |
| Sep 30, 2024 | -62.31 Mn |
| Jun 30, 2024 | -49.25 Mn |
| Mar 31, 2024 | -46.09 Mn |
| Dec 31, 2023 | -76.75 Mn |
| Sep 30, 2023 | -43.06 Mn |
| Jun 30, 2023 | -53.88 Mn |
| Mar 31, 2023 | -39.07 Mn |
| Dec 31, 2022 | -48.21 Mn |
| Sep 30, 2022 | -47.33 Mn |
| Jun 30, 2022 | -51.75 Mn |
| Mar 31, 2022 | -100.74 Mn |
| Dec 31, 2021 | -83.09 Mn |
| Sep 30, 2021 | -60.37 Mn |
| Jun 30, 2021 | -44.67 Mn |
| Mar 31, 2021 | -38.71 Mn |